Tamoxifen Citrate

Drug Usage Statistics, United States, 2004 - 2014

Number of Prescriptions Over Time (2004 - 2014)

Rank of Top Drugs Over Time

"Rank" refers to the frequency that a given medication is prescribed within a calendar year compared to all other medications. A rank of "4" would indicate that the medication was the fourth most commonly prescribed medication.

Year Rank Change
2004 165 -
2005 212  47
2006 306  94
2007 314  8
2008 274  40
2009 224  50
Year Rank Change
2010 209  15
2011 199  10
2012 290  91
2013 257  33
2014 234  23

Patient Out-Of-Pocket Cost Over Time (2004 - 2014)

"Out-of-pocket" cost refers to the payment made by the patient (either cash price or the copay amount). This value does not include reimbursement from a third party payer (eg, Medicare or private insurance) and does not represent the total drug cost.

Usage Statistics of Related Drugs

Drug Name Total Prescriptions (2014)
Tamoxifen Citrate (this drug) 2,586,544
Raloxifene Hydrochloride 2,348,131

Drug Synonyms

Drug synonyms are used during the sanitation and standardization process of "cleaning" the original data source (MEPS). Occassionally, brand names may be listed below that are no longer on the market or are very infrequently used.

Brand Name Synonyms
  • Nolvadex
  • Soltamox
Generic Drug Synonyms and Salts
  • Tamoxifen Citrate

FDA Approval Information

Established Pharmacologic Class (EPC): Estrogen Agonist/Antagonist
Initial FDA approval date: Prior to January 1, 1982
First FDA applicant: Astrazeneca Pharmaceuticals Lp
First dosage form: Tablet (oral)

Prescription data source: Medical Expenditure Panel Survey (MEPS) 2004-2014. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 17.0. Read more about the ClinCalc DrugStats database.

Search

Related Links

Follow Us!

New and Popular

Loading...

Open Menu

Cite This Page

Show AMA citation

Gorillas can't learn drug therapy ... but you can. The Top 250 Drugs by ClinCalc Academy
©2017 - ClinCalc LLC. All rights reserved.
Disclaimer - Privacy Policy - Contact Us
Updated Mar 4, 2017
Back to Top
Top